Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Eurofins-Cerep's FCF Yield % or its related term are showing as below:
XPAR:ALECR'
s FCF Yield % Range Over the Past 10 Years
Min: -4.43 Med: 0.11 Max: 12.7
Current: -4.43
During the past 13 years, the highest FCF Yield % of Eurofins-Cerep was 12.70%. The lowest was -4.43%. And the median was 0.11%.
XPAR:ALECR's FCF Yield % is ranked worse than 60.56% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.21
vs XPAR:ALECR: -4.43
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Eurofins-Cerep FCF Yield % Related Terms
Eurofins-Cerep FCF Yield % Historical Data
* Premium members only.
The historical data trend for Eurofins-Cerep's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALECR vs TMO, DHR, IDXX: FCF Yield % Comparison
For the Diagnostics & Research subindustry, Eurofins-Cerep's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins-Cerep FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins-Cerep's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Eurofins-Cerep's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins-Cerep (XPAR:ALECR) has a FCF Yield % of -4.43 as of Jul. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Eurofins-Cerep and its competitors. According to the industry distribution chart, Eurofins-Cerep ranks #129 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 60.6%.
Is Eurofins-Cerep's FCF Yield % too high?
Eurofins-Cerep's current FCF Yield % is -4.43. Based on the distribution chart, Eurofins-Cerep ranks #129 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Eurofins-Cerep has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Eurofins-Cerep's FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins-Cerep ranks #129 out of 213 companies for FCF Yield %. This places Eurofins-Cerep in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Eurofins-Cerep and its competitors. Eurofins-Cerep's current FCF Yield % is -4.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins-Cerep stock overvalued right now?
Eurofins-Cerep (XPAR:ALECR) has a current FCF Yield % of -4.43. The stock's GF Value™ is €20,317.48, compared to a current price of €16,300.00 — trading 19.8% below its estimated fair value. The current FCF Yield % is -4.43. Eurofins-Cerep's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Eurofins-Cerep (XPAR:ALECR), the current FCF Yield % is -4.43 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins-Cerep (XPAR:ALECR) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins-Cerep stock appears to be undervalued.
The current stock price of €16,300.00 is trading 19.8% below its estimated GF Value™ of €20,317.48.
Key valuation signals for XPAR:ALECR:
FCF Yield %: -4.43
GF Value™: €20,317.48 vs. price of €16,300.00 (19.8% below fair value)
No single metric tells the full story. See the XPAR:ALECR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins-Cerep SA provides in vitro pharmacology, in vitro ADME-Tox and in vivo PK services and solutions. The company also offers cost-effective drug discovery by identifying at early stages drug candidates and eliminating them. Some solutions provided by the company are - compound management, high-throughout screening, in vitro safety profiling, lead optimization profiling, in vitro ADME profiling, and in vivo PK.
27GF Score
Get the complete analysis for XPAR:ALECR
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALECR has been successfully added to your 
